| chronic pain (diagnosis)

Lyrica vs Prialt

Side-by-side clinical, coverage, and cost comparison for chronic pain (diagnosis).

Deep comparison between: Lyrica vs Prialt with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsPrialt has a higher rate of injection site reactions vs Lyrica based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Prialt but not Lyrica, including UnitedHealthcare

Category

Lyrica

Prialt

At A Glance

RouteOral

Frequency2-3 times daily

Classalpha2-delta calcium channel ligand

RouteIntrathecal infusion

FrequencyContinuous infusion

ClassN-type calcium channel blocker

Indications

Peripheral Nervous System Diseases
Epilepsy
Fibromyalgia
chronic pain (diagnosis)

chronic pain (diagnosis)

Dosing

Peripheral Nervous System Diseases Begin at 150 mg/day in 3 divided doses; may increase to max 300 mg/day within 1 week; oral.

chronic pain (diagnosis) PHN: begin at 150 mg/day (75 mg BID or 50 mg TID), max up to 600 mg/day. Spinal cord injury neuropathic pain: begin at 150 mg/day (75 mg BID), max 600 mg/day; oral.

Epilepsy Adults: begin at 150 mg/day in 2 or 3 divided doses, max 600 mg/day. Pediatric >=30 kg: begin 2.5 mg/kg/day, max 10 mg/kg/day. Pediatric <30 kg: begin 3.5 mg/kg/day, max 14 mg/kg/day; oral.

Fibromyalgia Begin at 150 mg/day (75 mg BID); may increase to 300 mg/day within 1 week; max 450 mg/day; oral.

chronic pain (diagnosis) Initiate at no more than 2.4 mcg/day (0.1 mcg/hr) intrathecally; titrate by up to 2.4 mcg/day at intervals no more than 2-3 times per week; maximum recommended dose 19.2 mcg/day (0.8 mcg/hr).

Contraindications

Known hypersensitivity to pregabalin or any of its components

Known hypersensitivity to ziconotide or any formulation component
Any concomitant treatment or medical condition rendering intrathecal administration hazardous
Infection at the microinfusion injection site
Uncontrolled bleeding diathesis
Spinal canal obstruction that impairs circulation of CSF
Pre-existing history of psychosis

Drug Interactions

1242View drug interactions

478View drug interactions

Adverse Reactions

Most common (>=5%) Dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, thinking abnormal

Serious Angioedema, hypersensitivity, suicidal behavior and ideation, respiratory depression, peripheral edema, weight gain, tumorigenic potential, ophthalmological effects, creatine kinase elevations, decreased platelet count, PR interval prolongation

Postmarketing Headache, nausea, diarrhea, gynecomastia, breast enlargement, bullous pemphigoid, life-threatening respiratory depression with opioids or CNS depressants

Most common (>=25%) dizziness, nausea, confusional state, nystagmus

Serious acute renal failure, atrial fibrillation, cerebrovascular accident, sepsis, meningitis, psychotic disorder, suicidal ideation, respiratory distress, rhabdomyolysis, fatal aspiration pneumonia, suicide attempt

Postmarketing hypersensitivity reactions including angioedema, bullous dermatitis, skin ulcers, skin exfoliation, burning skin sensation

Pharmacology

Pregabalin binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in CNS tissues, reducing calcium-dependent release of pro-nociceptive neurotransmitters in the spinal cord and exerting antiseizure effects; it is a structural GABA analogue but does not act directly on GABA receptors, sodium channels, or opiate receptors.

Ziconotide is an N-type calcium channel blocker; it binds to N-type calcium channels on primary nociceptive afferent nerves in the dorsal horn of the spinal cord, blocking excitatory neurotransmitter release from afferent nerve terminals and producing antinociception.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Lyrica